Cargo Therapeutics, INC Form 4 insider transactions

Reid M. Huber, a director at Cargo Therapeutics, acquired stock options for 23,742 shares of common stock on June 4, 2024.

Director John A. Orwin acquired stock options for 23,742 shares of Cargo Therapeutics, Inc. on June 4, 2024.

Director Jane Henderson reports the acquisition of stock options in Cargo Therapeutics, Inc.

Samsara BioCapital, through its affiliated entities, acquired 294,000 shares of CARGO Therapeutics at $17 per share, increasing its indirect beneficial ownership to 4,415,689 shares.

Kapil Dhingra, a director at Cargo Therapeutics, acquired stock options for 49,265 shares at an exercise price of $19.89 on April 15, 2024.

Ginna Laport, Chief Medical Officer of Cargo Therapeutics, acquired 100,000 stock options on March 1, 2024, as reported in a Form 4 filing with the SEC.

Shishir Gadam, Chief Technical Officer of Cargo Therapeutics, was granted stock options for 100,000 shares on March 1, 2024, according to a Form 4 filing.

Anup Radhakrishnan, CFO of Cargo Therapeutics, received stock options for 130,000 shares on March 1, 2024, vesting monthly over four years.

Gina Chapman, CEO of Cargo Therapeutics, reports the acquisition of stock options.